FRAMINGHAM, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the H.C. Wainwright 20th Annual Global Investment Conference. The conference is being held on September 4-6, 2018 at The St. Regis, New York.
Chief Executive Officer, Terrence W. Norchi, MD, is scheduled to provide a corporate update on Wednesday, September 5 at 2:10 PM ET in Astor Suite A. Dr. Norchi and Chief Financial Officer, Mr. Richard Davis, will be available to meet with investors who are registered to attend the conference. If you are an investor and wish to attend the Company's presentation or schedule a meeting, please click the following link: www.rodmanevents.com.
To access the live webcast, please visit: http://wsw.com/webcast/rrshq28/arth.
The presentation will be available for download at: https://www.archtherapeutics.com.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5™ Topical Gel and AC5™ Surgical Hemostatic Device.

